Sign In
Buy AEMD
$1.36
-0.0200 (-1.45%)
At Close: Jun 23, 2026
/PRNewswire/ -- USA News Group – A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that...
Aethlon Medical Announces Closing of $5 Million Public Offering
09:18pm, Tuesday, 17'th Dec 2019
Aethlon Medical, Inc. (Nasdaq: AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the
Aethlon Medical Announces Pricing of $5 Million Public Offering
12:00pm, Friday, 13'th Dec 2019
Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the p
Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
10:04am, Friday, 15'th Nov 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
08:15pm, Friday, 01'st Nov 2019
SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening disea
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019
07:17pm, Tuesday, 29'th Oct 2019
SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial result
AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…
11:00am, Monday, 28'th Oct 2019
By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated immin
Xconomy: Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPO
12:19pm, Tuesday, 30'th Apr 2019
Do Wall Street investors believe that exosomes, the tiny bubbles once thought to be just cellular garbage bins, may be the key to treating a slew of
Xconomy: VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M
11:55am, Wednesday, 29'th Nov 2017
Codiak BioSciences, the startup run by former Biogen (NASDAQ: ]) research chief Doug Williams, has rung up its third big round of cash in two years. The
